Literature DB >> 22203607

The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.

Ann R Holmes1, Mikhail V Keniya, Irena Ivnitski-Steele, Brian C Monk, Erwin Lamping, Larry A Sklar, Richard D Cannon.   

Abstract

Resistance to the commonly used azole antifungal fluconazole (FLC) can develop due to overexpression of ATP-binding cassette (ABC) and major facilitator superfamily (MFS) plasma membrane transporters. An approach to overcoming this resistance is to identify inhibitors of these efflux pumps. We have developed a pump assay suitable for high-throughput screening (HTS) that uses recombinant Saccharomyces cerevisiae strains hyperexpressing individual transporters from the opportunistic fungal pathogen Candida albicans. The recombinant strains possess greater resistance to azoles and other pump substrates than the parental host strain. A flow cytometry-based HTS, which measured increased intracellular retention of the fluorescent pump substrate rhodamine 6G (R6G) within yeast cells, was used to screen the Prestwick Chemical Library (PCL) of 1,200 marketed drugs. Nine compounds were identified as hits, and the monoamine oxidase A inhibitor (MAOI) clorgyline was identified as an inhibitor of two C. albicans ABC efflux pumps, CaCdr1p and CaCdr2p. Secondary in vitro assays confirmed inhibition of pump-mediated efflux by clorgyline. Clorgyline also reversed the FLC resistance of S. cerevisiae strains expressing other individual fungal ABC transporters (Candida glabrata Cdr1p or Candida krusei Abc1p) or the C. albicans MFS transporter Mdr1p. Recombinant strains were also chemosensitized by clorgyline to other azoles (itraconazole and miconazole). Importantly, clorgyline showed synergy with FLC against FLC-resistant C. albicans clinical isolates and a C. glabrata strain and inhibited R6G efflux from a FLC-resistant C. albicans clinical isolate. Clorgyline is a novel broad-spectrum inhibitor of two classes of fungal efflux pumps that acts synergistically with azoles against azole-resistant C. albicans and C. glabrata strains.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22203607      PMCID: PMC3294898          DOI: 10.1128/AAC.05706-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2.

Authors:  Ann R Holmes; Sarah Tsao; Soo-Wee Ong; Erwin Lamping; Kyoko Niimi; Brian C Monk; Masakazu Niimi; Aki Kaneko; Barbara R Holland; Jan Schmid; Richard D Cannon
Journal:  Mol Microbiol       Date:  2006-08-30       Impact factor: 3.501

2.  Inhibition of fungal ABC transporters by unnarmicin A and unnarmicin C, novel cyclic peptides from marine bacterium.

Authors:  Koichi Tanabe; Erwin Lamping; Kyoko Adachi; Yukie Takano; Kazutaka Kawabata; Yoshikazu Shizuri; Masakazu Niimi; Yoshimasa Uehara
Journal:  Biochem Biophys Res Commun       Date:  2007-10-29       Impact factor: 3.575

Review 3.  Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.

Authors:  Zeina A Kanafani; John R Perfect
Journal:  Clin Infect Dis       Date:  2008-01-01       Impact factor: 9.079

4.  Outwitting multidrug resistance to antifungals.

Authors:  Brian C Monk; Andre Goffeau
Journal:  Science       Date:  2008-07-18       Impact factor: 47.728

5.  Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver.

Authors:  Jonathan M Maher; Xingguo Cheng; Angela L Slitt; Matthew Z Dieter; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2005-04-15       Impact factor: 3.922

6.  Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus.

Authors:  T C White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

7.  Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Barbara Fiori; Stefania Ranno; Riccardo Torelli; Giovanni Fadda
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 8.  Antifungal potential of disulfiram.

Authors:  Seema Khan; Smita Singhal; Tarun Mathur; Dilip J Upadhyay; Ashok Rattan
Journal:  Nihon Ishinkin Gakkai Zasshi       Date:  2007

9.  Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates.

Authors:  Alix Coste; Anna Selmecki; Anja Forche; Dorothée Diogo; Marie-Elisabeth Bougnoux; Christophe d'Enfert; Judith Berman; Dominique Sanglard
Journal:  Eukaryot Cell       Date:  2007-08-10

10.  Identification of a region important for human monoamine oxidase B substrate and inhibitor selectivity.

Authors:  J Grimsby; M Zentner; J C Shih
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

View more
  38 in total

Review 1.  A high throughput flow cytometric assay platform targeting transporter inhibition.

Authors:  George P Tegos; Annette M Evangelisti; J Jacob Strouse; Oleg Ursu; Cristian Bologa; Larry A Sklar
Journal:  Drug Discov Today Technol       Date:  2014-06

Review 2.  Antifungal adjuvants: Preserving and extending the antifungal arsenal.

Authors:  Arielle Butts; Glen E Palmer; P David Rogers
Journal:  Virulence       Date:  2016-07-26       Impact factor: 5.882

Review 3.  Targeting efflux pumps to overcome antifungal drug resistance.

Authors:  Ann R Holmes; Tony S Cardno; J Jacob Strouse; Irena Ivnitski-Steele; Mikhail V Keniya; Kurt Lackovic; Brian C Monk; Larry A Sklar; Richard D Cannon
Journal:  Future Med Chem       Date:  2016-07-27       Impact factor: 3.808

4.  Synthetic Organotellurium Compounds Sensitize Drug-Resistant Candida albicans Clinical Isolates to Fluconazole.

Authors:  L F Reis de Sá; F T Toledo; A C Gonçalves; B A Sousa; A A Dos Santos; P F Brasil; V A Duarte da Silva; A C Tessis; J A Ramos; M A Carvalho; E Lamping; A Ferreira-Pereira
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  Potent Synergistic Interactions between Lopinavir and Azole Antifungal Drugs against Emerging Multidrug-Resistant Candida auris.

Authors:  Hassan E Eldesouky; Ehab A Salama; Nadia A Lanman; Tony R Hazbun; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

6.  Multidrug-resistant transporter mdr1p-mediated uptake of a novel antifungal compound.

Authors:  Nuo Sun; Dongmei Li; William Fonzi; Xin Li; Lixin Zhang; Richard Calderone
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

7.  Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs.

Authors:  Hassan E Eldesouky; Abdelrahman Mayhoub; Tony R Hazbun; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

8.  Quinacrine inhibits Candida albicans growth and filamentation at neutral pH.

Authors:  Vibhati V Kulkarny; Alba Chavez-Dozal; Hallie S Rane; Maximillian Jahng; Stella M Bernardo; Karlett J Parra; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

Review 9.  Antifungal drug screening: thinking outside the box to identify novel antifungal scaffolds.

Authors:  Sarah R Beattie; Damian J Krysan
Journal:  Curr Opin Microbiol       Date:  2020-04-24       Impact factor: 7.934

Review 10.  The effect of biomaterials and antifungals on biofilm formation by Candida species: a review.

Authors:  M Cuéllar-Cruz; A Vega-González; B Mendoza-Novelo; E López-Romero; E Ruiz-Baca; M A Quintanar-Escorza; J C Villagómez-Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.